Colorectal Cancer Incidence Turns Up Again Across U.S. Age Groups
Colorectal cancer is reversing a decline that held for more than two decades. New national analysis shows the first overall rise in incidence since 2000, with higher rates now appearing across nearly every age group under 70 rather than remaining confined to younger adults. The shift is clinically important because it widens the population at risk and weakens the assumption that the recent surge is mainly an early-onset phenomenon.
The age-adjusted U.S. incidence rate fell from 55.2 cases per 100,000 people in 2000 to 36.7 in 2022, then increased to 38.3 in 2023. That single-year increase does not erase the earlier gains from screening and early detection, but it does mark a meaningful reversal after years of steady progress. For clinicians, epidemiologists, and health systems, the pattern raises a harder question than a simple uptick in younger patients: why is the curve rising again in older adults who have historically benefited most from screening?
One sentence captures the shift plainly: this is no longer only a story about people under 50.
Caitlin Murphy, PhD, MPH, and colleagues examined National Cancer Institute incidence data from 2000 through 2023 and found that the increase now extends through age 65 to 69. The pattern fits a birth cohort effect, in which people born during the same era share exposures or risk profiles that become visible as they age. In practical terms, a person born in the 1960s may carry a different colorectal cancer risk trajectory than someone born in the 1940s, even at the same chronological age, because their lifetime environmental, dietary, metabolic, and behavioral exposures have not been the same.
Screening Explains Part of the Rise, But Not All of It
The sharpest annual increase appeared in adults ages 45 to 49, where incidence rose 12.76% per year from 2019 through 2023. Some of that surge is expected. National screening recommendations lowered the starting age for average-risk adults from 50 to 45, and expanded testing naturally identifies more cancers that would otherwise remain undetected. In that sense, higher incidence in this age band partly reflects more effective case finding, not necessarily more disease alone.
But screening cannot account for the entire pattern. Rates are also rising in adults ages 65 to 69, while the decline has stalled among those ages 70 to 74. Both age groups have long had substantial access to screening, and roughly 80% are current with recommended testing. When incidence increases despite broad screening uptake, the explanation has to extend beyond detection alone. The most plausible interpretation is that additional risk drivers are counteracting decades of progress.
A second sentence stands on its own: screening is finding more cancer, but it is not the only reason cancer is increasing.
The analysis also addressed a major possible confounder. Screening and diagnosis were disrupted during the COVID-19 pandemic, and delayed procedures can distort cancer statistics. Even so, the upward trend remained after removing 2020 and 2021 data, and screening activity had largely returned to previous levels by January 2021. That makes the pandemic an incomplete explanation for the rise seen in 2023.
Sonia Kupfer, MD, emphasized the practical consequence: the rising numbers should intensify efforts to identify modifiable causes. That is especially important because the current trend could translate into far more patients needing treatment, surveillance, and survivorship care as newer birth cohorts age into the decades when colorectal cancer becomes more common.
Early-Onset Disease May Be Pointing to a Broader Exposure Problem
The findings connect directly to the larger concern over early-onset colorectal cancer. American Cancer Society data show incidence among adults ages 20 to 49 rose by about 3% per year from 2013 to 2022. The new study suggests that whatever is driving that increase may not be limited to younger adults. If the same force is now influencing older groups, the exposure is likely widespread, persistent, and biologically relevant across generations.
Researchers are now looking beyond standard screening metrics and asking whether environmental chemical exposures could be part of the explanation. Murphy’s team is working with toxicologist Xin Hu, PhD, to analyze small blood samples for signals of thousands of chemical exposures at once. That kind of approach is useful because colorectal carcinogenesis rarely has a single cause; it often emerges from the interaction of inflammation, microbial changes, diet, obesity, inherited susceptibility, and exposures that may alter epithelial repair or promote malignant transformation over time.
The next step moves from association to biology. The investigators plan to work with Kupfer to examine how candidate chemicals affect colon tissue using organoids, laboratory-grown models that reproduce important features of the colon. These models can show how exposures influence cell proliferation, DNA damage responses, barrier integrity, and other pathways relevant to tumor initiation. If a specific exposure pattern can be linked to measurable tissue effects, the field gets closer to identifying not just who is at risk, but why.
Screening Still Matters, Especially When Symptoms Appear Early
Even with uncertainty about the cause of the rise, the clinical response has not changed. Average-risk adults should begin regular colorectal cancer screening at age 45 and continue through age 75. Colonoscopy remains the gold standard, but stool tests and newer blood-based options also play a role depending on access, preference, and follow-up capacity. Different tests serve different purposes, and each has its own interval and limitations.
Patients younger than 45 should not assume age alone protects them. Rectal bleeding, persistent changes in bowel habits, and unexplained weight loss still warrant evaluation, especially when family history or genetic risk is present. Waiting for the screening age to arrive can delay diagnosis in the very group where case counts have drawn the most attention.
Murphy and colleagues are continuing to follow national registry data as new numbers emerge. The key limitation is also the central unresolved issue: incidence data show the rise, but they do not identify the causal driver. Until the exposure profile becomes clearer, clinicians are left managing a growing burden of disease while prevention science tries to catch up.